Study the Antibacterial Mechanism of Diclofenac and its Activity Alone or Combined with Ciprofloxacin in Treating Urinary Tract Infection
Abstract
This study aimed to compare the effects of diclofenac, ciprofloxacin and their combination groups on urine tract infection (U.T.I.s) caused by resistance E coli 0157 H7 in vitro and in vivo. Two hundred urine samples were collected from adult women patients suffering from U.T.I.s from February 2022 to July 2022. The urine specimen was cultured on the blood agar and then incubated at 37°C for (1-2) days; MacConkey agar is the media used for determining the biochemistry results, and identification by Rapidchek test which was performed on typical colonies from the selective plate. The M.I.C effect of Diclofenac began at (25600µg/ml) against resistance E coli 0157H7 while M.I.C of ciprofloxacin it was at (0.96mg/ml), but M.I.C of a combination between (diclofenacn+ciprofloxacin) it was at (400+0.48) mg/ml. Resistance induction assay,with the ciprofloxacin has increased four times, while with the diclofenac has doubled, whilst the combination between (diclofenacn+ciprofloxacin) has no changed after 21 days, according to M.I.C.in the time-kill assay, it was proved that the ciprofloxacin and the combination between (diclofenacn+ciprofloxacin) works after 6 hours, compared to the diclofenac, which started to reduce bacterial counting after 40. After that, the examination was carried out by scanning electronic microscope (S.E.M.) to exam the mechanics of diclofenac,work which was found that it was works as anti-biofilm In this study, forty-eighth (48) rabbits were used and divided…
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.